Strength training on GLP-1s: what the fat loss claims miss

What's this video probably claiming?

Based on the hashtags and caption framing, @jmethod is almost certainly walking viewers through a strength training program designed for fat loss, with particular emphasis on glute development and body recomposition for people over 40. The GLP-1 category tag strongly suggests the creator is positioning this workout approach as compatible with, or optimized for, people currently using semaglutide or tirzepatide. The "results earned" framing implies before-and-after transformations tied to Team Endure's programming. The pitch is likely something like: GLP-1 medications reduce appetite and drive weight loss, but without the right resistance training, you'll lose muscle alongside fat, so here's the fix. That's actually a legitimate concern. But the way fitness creators tend to frame it, the training becomes the magic variable, when the clinical picture is considerably more complicated than that.

What does the science actually show?

The muscle loss concern on GLP-1s is real and worth taking seriously. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), tirzepatide produced average weight loss of 20.9% body weight over 72 weeks, but roughly 40% of that loss was lean mass, depending on the cohort. Semaglutide data from the STEP trials shows similar patterns. Resistance training is the evidence-backed intervention for attenuating that lean mass loss. Villanueva et al. (2017, Obesity Reviews) confirmed that progressive resistance training during caloric restriction preserves significantly more fat-free mass than cardio or no exercise. For adults over 40, hormonal shifts, particularly declining estrogen and testosterone, make muscle preservation harder, which gives the age-specific hashtag some clinical grounding. Where the science gets murkier is whether a specific programmed glute focus provides outcomes meaningfully different from general lower-body resistance training in this population.

Where does the social media noise diverge from clinical reality?

The biggest divergence is the implied causation between a specific training program and the results shown. GLP-1 medications alone produce substantial body composition changes. When you layer a caloric deficit driven by semaglutide or tirzepatide on top of a resistance program, it becomes nearly impossible to attribute outcomes to the training specifically. Creators rarely acknowledge this. There's also a quiet assumption in fat-loss-over-40 content that muscle gain and fat loss happen simultaneously at meaningful rates. True body recomposition in a significant caloric deficit is limited. Barakat et al. (2020, Strength and Conditioning Journal) found recomposition is most pronounced in untrained individuals or those returning after a break, not in people who've been training consistently. The glutes focus is also worth scrutinizing. Glute hypertrophy requires progressive mechanical tension over months. On an aggressive GLP-1-driven deficit, hypertrophy is genuinely harder to achieve, which most creators in this space quietly ignore.

What should you actually know?

If you're on a GLP-1 medication and considering adding structured resistance training, the evidence supports doing it. It's not hype. The problem is evaluating which program to follow and understanding what you can realistically expect. Protein intake is arguably as important as the training itself. Carbone and Pasiakos (2019, Nutrients) found protein intakes above 1.6g per kilogram of body weight are associated with better lean mass retention during energy restriction. GLP-1-driven appetite suppression can make hitting protein targets genuinely difficult, which is a practical challenge most fitness program sellers don't address. For people over 40, recovery capacity is also different. Two to three resistance sessions per week with adequate volume per muscle group is supported by Schoenfeld and Grgic (2017, Journal of Strength and Conditioning Research) as effective for hypertrophy without excessive recovery demand. The program behind a paywall might be fine. But the results in the video are likely driven heavily by the medication, not the specific training split.